Analysts expect Corium International Inc (NASDAQ:CORI) to announce $7.82 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Corium International’s earnings, with the highest sales estimate coming in at $7.83 million and the lowest estimate coming in at $7.81 million. Corium International posted sales of $9.44 million during the same quarter last year, which suggests a negative year over year growth rate of 17.2%. The business is expected to issue its next quarterly earnings report on Thursday, November 15th.
On average, analysts expect that Corium International will report full-year sales of $34.51 million for the current financial year, with estimates ranging from $34.15 million to $34.86 million. For the next year, analysts anticipate that the business will report sales of $38.10 million per share, with estimates ranging from $37.76 million to $38.44 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that follow Corium International.
Corium International (NASDAQ:CORI) last issued its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.04. Corium International had a negative return on equity of 276.89% and a negative net margin of 155.21%. The firm had revenue of $7.67 million during the quarter, compared to analyst estimates of $6.72 million.
CORI has been the topic of several research reports. Cantor Fitzgerald reissued a “buy” rating and issued a $14.00 target price on shares of Corium International in a research report on Friday, August 10th. Zacks Investment Research raised Corium International from a “sell” rating to a “hold” rating in a research report on Tuesday, August 14th. HC Wainwright reissued a “buy” rating and issued a $13.00 target price on shares of Corium International in a research report on Monday, August 13th. BidaskClub raised Corium International from a “strong sell” rating to a “sell” rating in a research report on Wednesday, June 13th. Finally, ValuEngine downgraded Corium International from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 17th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $12.80.
Shares of NASDAQ CORI traded down $0.07 during mid-day trading on Monday, hitting $9.72. The stock had a trading volume of 3,999 shares, compared to its average volume of 271,672. The company has a debt-to-equity ratio of 2.83, a current ratio of 7.61 and a quick ratio of 7.47. Corium International has a twelve month low of $7.17 and a twelve month high of $13.93. The company has a market cap of $353.80 million, a price-to-earnings ratio of -5.97 and a beta of 1.60.
In related news, insider Joseph J. Sarret sold 3,565 shares of the company’s stock in a transaction on Friday, August 17th. The stock was sold at an average price of $9.01, for a total value of $32,120.65. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Parminder Singh sold 3,133 shares of the company’s stock in a transaction on Friday, August 17th. The shares were sold at an average price of $9.01, for a total value of $28,228.33. The disclosure for this sale can be found here. Over the last three months, insiders sold 119,965 shares of company stock worth $1,060,275. 30.80% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MetLife Investment Advisors LLC acquired a new stake in Corium International during the 4th quarter worth about $123,000. DekaBank Deutsche Girozentrale acquired a new stake in Corium International during the 1st quarter worth about $167,000. Engineers Gate Manager LP acquired a new stake in Corium International during the 2nd quarter worth about $215,000. Alps Advisors Inc. acquired a new stake in Corium International during the 2nd quarter worth about $420,000. Finally, Citadel Advisors LLC acquired a new stake in Corium International during the 1st quarter worth about $455,000.
Corium International Company Profile
Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.
Recommended Story: Growth Stocks, What They Are, What They Are Not
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.